Research programme: embryonic stem cell therapies - ES Cell International

Drug Profile

Research programme: embryonic stem cell therapies - ES Cell International

Alternative Names: ESI-014; ESI-017; ESI-035; ESI-049; ESI-051; ESI-053

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ES Cell International
  • Developer BioTime; ES Cell International; University of California at Irvine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Heart failure; Huntington's disease

Most Recent Events

  • 15 Aug 2016 BioTime receives patent allowance for Embryonic stem cell therapies in USA, Australia, Canada, China, India, Israel and Japan
  • 27 Apr 2015 Bio Time and University of California at Irvine entered into collaboration to develop human Embryonic Stem (hES) cell lines for Huntington’s Disease
  • 27 Apr 2015 Preclinical trials in Huntington's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top